FY11/12FY11/12

FY 2011FY 2011//1212

Annual Results PresentationAnnual Results Presentation

(12 Months Ended March 31, 2012)(12 Months Ended March 31, 2012)

Investor Presentation Jun 2012

Data and information contained in this presentation is provided for informational purposes only. GoldenMeditech Holdings Limited takes no liabilities for any errors or delays in the content, or for any actionstaken in reliance thereon.

This presentation and subsequent discussions may contain forward-looking statements that are basedon the current beliefs, assumptions, expectations, estimates, and projections of the management ofGolden Meditech Holdings Limited about its businesses and the industries and markets in which it

Disclaimer

2

Golden Meditech Holdings Limited about its businesses and the industries and markets in which itoperates. These forward-looking statements include, without limitation, statements relating to revenues,earnings and stock performance. The words “believe”, “intend”, “expect”, “anticipate”, “project”,“estimate”, “predict” and similar expressions are also intended to identify the forward-looking statements.These statements are not guarantees of future performance and are subject to various risks anduncertainties, including, but not limited to, changes in legal, financial and regulatory frameworks, actualdemand, exchange rate fluctuations, market shares, competition, environmental risks, internationaleconomic and financial market conditions, project approval, cost estimates and other risks, which arebeyond the control of Golden Meditech Holdings Limited and are difficult to predict. Consequently, futurefinancial results could differ materially from those expressed or forecasted in the forward-lookingstatements.

• Company Profile

• FY11/12 Highlights

• Review of Operations

• Recent Updates on the Group’s Businesses

Agenda

• Recent Updates on the Group’s Businesses

• Q&A

3

Company Profile

The Healthcare Services Segment

•GM Hospital Group (“GMHG”) consists of:

• The operation of 2 Daopei Hospitals (Beijing & Shanghai), as leading haematologyhospitals in China, and pending expansion of Beijing Daopei by 2012

Golden Meditech Holdings Limited is a leading integrated healthcare enterprise which focuses on China’s

healthcare industry. It’s core operations are categorized into two key segments:

�

4

hospitals in China, and pending expansion of Beijing Daopei by 2012

• The operation of Shanghai East International Medical Centre (“SEIMC”), providing premium healthcare services in the vicinity of Shanghai

•Pioneer in specialized medical insurance administration solutions provider in China, GM-Medicare (China) Company Ltd. (“GM-Medicare”)

• Founding shareholder of China Cord Blood Corporation (“CCBC”), the largest cord blood banking operator in China

The Medical Devices Segment

•Leading medical devices manufacturer in China - Beijing Jingjing Medical Equipment Co., Ltd. (Largest Shareholder of “BJJJ”)

•Second largest shareholder of China’s leading medical equipment distributor, China National Medical Equipment Industry Corporation (“CMIC”)

�

Golden Meditech

(801.HK; 910801.TW)

Medical Devices

Segment

Healthcare Services

Segment

Strategic

Investment

Group Structure

5

NB: Entities highlighted in BLUE represents publicly listed entities.

Beijing Jingjing Medical

Equipment Co., Ltd.

China National Medical

Equipment Co., Ltd

China Cord Blood

Corporation

(NYSE: CO)

GM Hospital

Group

Beijing

Daopei Hospital

Shanghai

Daopei Hospital

Shanghai East International

Medical Center

GM-Medicare Management

(China) Co., Ltd.

Fortress Group Limited

(formerly known as FunTalk

China)

Chinese Herbal Medicine Business

FY11/12 Highlights• Turnover �32% to HK$433.2mm, solid growth from all business segments

• Revenue from Healthcare Services Segment �84% from HK$80.4mm to HK$147.9mm Y-o-Y

• Medical Devices Segment posted solid performance, churning in HK$257.8mm in revenue �5% Y-o-Y

• CCBC contributed HK$63.7mm �53% Y-o-Y

• Adjusted Profit Attributable to Shareholders�13% *

• Declared a final dividend of HK1 cent (Including shares repurchased, returning approx. HK3.4 cents per share toshareholders, approx. 40% of current year profit after tax)

6

shareholders, approx. 40% of current year profit after tax)

• Major progress and breakthrough in hospital management:

– Acquired Shanghai East International Medical Center (“SEIMC”)

– Acquired new premise for Beijing Daopei hospital expansion - 5 fold of current capacity

– Group increased stake in hospital management business from 60% to 75% through share swap with New

Horizon Capital, which now owns 6.6% of the Group’s shares

• GM-Medicare trial launched in FY11/12, contributing to the Group’s revenue for the first time

• Group disposed 3% stake in Fortress Group Limited (A SPV privatized FunTalk China) for US$15mm in September

2011 subsequent to its privatisation, thereafter, the Group’s shareholdings in Fortress became 29.4%.

* Excluding the non-cash and non-operating loss of HK$84,523,000 (FY10/11: non-cash and non-operating gain of HK$132,796,000) due to volatility in the global

financial markets which led to decline/ increase in the fair value of listed securities and previously issued convertible notes

FY2011/12 Results SummaryHK$’000 FY2011/12 FY2010/11 % Change

Revenues

Hospital Management Service Income

Medical Insurance Administration Service Income

Medical Devices Sales

Medical Accessories Sales

Sales Income from Chinese Herbal Medicine Business

147,110

811

153,603

104,209

27,489

80,412

-

148,581

96,170

2,903

83%

N/A

3%

8%

847%

433,222 328,066 32%

Share of Profit from Associates

7

Share of Profit from Associates

China Cord Blood Corporation (“CCBC”, CO.US)

China National Medical Equipment Industry Corp. (CMIC)

Fortress Group Limited (A SPV Privatized FunTalk China in

August 2011)

63,683

11,384

94,509

41,720

7,408

73,811

53%

54%

28%

Profit After Tax 171,306 359,234 -52%

Adjusted Profit Attributable to Shareholders* 237,400 210,412 13%

Profit Attributable to Shareholders 152,877 343,208 -55%

Adjusted Earnings Per Share (Basic)# 12.0 HK cents 12.2 HK cents -2%

Earnings Per Share (Basic) 7.7 HK cents 19.9 HK cents -61%

*Excluding the non-cash and non-operating loss of HK$84,523,000 (FY10/11: non-cash and non-operating gain of

HK$132,796,000) due to volatility in the global financial markets which led to decline/increase in the fair value of listed securities

and previously issued convertible notes# Based on Adjusted Profit Attributable to Shareholders

Strong Balance Sheet

HK$ ‘000 FY2011/12 FY2010/11

NAV per share (HK$) 2.47 2.25

Total Assets 6,979,375 6,040,692

Total Assets less Current Liabilities 5,393,986 5,718,161

Net Assets Value 4,921,800 4,256,354

8

Net Assets Value 4,921,800 4,256,354

Cash and bank balances 819,963 770,591

Gearing ratio 13.3% 16.0%

• Cash and bank deposits amounted to HK$820mm (FY2010/11: HK$771mm); total interest bearing debt stood

at HK$654mm (FY2010/11: HK$681mm)

• The Group is in a satisfactory financial position with sufficient capital and financial resources to meet future

business development needs

Highlights of Healthcare Services Segment

CCBC separately listed –

deconsolidated with contribution

as affiliate

Healthcare Services

517,63

137,809221,221

298,857404,430

471,268

51,763

80,412

147,110

200,000

400,000

600,000

Hospital Management

Cord Blood Banking

(HK$ ‘000)

9

• Hospital Management Business reported impressive second full-year revenue since the

Group completed the acquisition of the hospital group in June 2009

• Group acquired 56% of Shanghai East International Medical Center for US$10mm in cash and

shares. SEIMC boasts a strong reputation in municipal Shanghai serving expatriate and high

end hospital markets

• Beijing Daopei Hospital is also due for expansion with a new facility in Haidian District in

Beijing. New facility will host 500 beds over a floor area of 74,035 m2

Strengthening Healthcare Services Segment

137,809221,221

0

FY07/08 FY08/09 FY09/10 FY10/11 FY11/12

� Summary of Hospital Management Division

� First foreign company to have a nation-wide hospital management license, to providehospital management consultancy services

� Currently operating 3 hospitals:

� Daopei Hospitals - 2 largest privately-owned haematology hospitals in China, in Beijingand Shanghai – with 100 beds each (Beijing Daopei Hospital expansion – see below)

Highlights of Healthcare Services Business

10

and Shanghai – with 100 beds each (Beijing Daopei Hospital expansion – see below)

� Shanghai East International Medical Center (completed acquisition in August 2011) topenetrate high-end expatriate market

� Group increased stake in hospital management company from 60% to 75% by share swapwith New Horizon Capital (131,756,756 shares of the Group’s at HK$1.48). New HorizonCapital owns 6.6% interest in Golden Meditech Holdings as of today

� Acquisitions complementary with core strategy to achieve long-term growth and become aleader in China’s hospital management industry both through organic growth and strategicexpansion

Total number of beds including SEIMC and New Hospitals will be close to 700 beds by 2012, about 2.5 times current capacity

Target Expansion of Beijing Daopei Hospital in 2012 – Haidian District, Beijing

• Group acquired 57.9% of a partially completed new hospital facility in Beijing’s Haidian District for

total consideration of HK$600mm

• Site area is approx. 18,692 m2; permissible construction area of 74,035 m2 with 500 beds

• Expected to be completed by the end of 2012

• Considerably relieve the shortage in bed spaces and cater to patients who are seeking to be

admitted based on the hospital’s strong reputation

11Artist’s impressions of proposed designs for new hospital in Beijing only

admitted based on the hospital’s strong reputation

• CCBC (CO.US) posted impressive growth and contributed HK$63.7mm to the Group.

Highlights of Healthcare Services Business

• The Group currently owns 41.4% of CCBC’s shares

• CCBC’s FY2012 results

– FY2012 revenue up 12% Y-O-Y to RMB380.5mm

– Total accumulative subscribers reached 239,754

– Gross margin remained at 77.2%

– Operating income increased 9% to RMB134.8mm

– Net income attributable to shareholders up 43.9% to RMB132.0mm

12

• GM-Medicare Management (China) Co., Ltd., is a pioneering specialist in medical insurance

administration service provider in China

• Established in April 2010 as a sino-foreign joint venture with leading U.S. health

Highlights of Healthcare Services Business

Medical Insurance Administration Service Business

13

• Established in April 2010 as a sino-foreign joint venture with leading U.S. health

maintenance organizations, SynerMed & EHS

• Churned in maiden revenue for the interim period upon a trial launched during the interim

period – positive feedback from users and in line with management expectations

• GM Medicare will leverage the extensive hospital network, China market knowledge

construction of backbone systems to create one-stop shop

• Advanced IT infrastructure tailor-made for China market

Highlights of Medical Devices Segment

224,446 203,387146,249 148,581 153,603

200,000

300,000

400,000

Medical Devices

Medical Accessories

Medical Devices

Strategic Price Cut

(HK$ ‘000)

14

• Revenue up 5% to HK$257.8mm, mostly attributable to increase in device utilization

• The segment accounted for 60% of Group’s total revenue, and with medical devices sales

accounted for 60% of segmental revenue while accessories sales accounted for 40%

• Implementation of the MOH’s “Regulation Governing Hospital Standard Accreditation and

Administration” (綜合醫院評析標準) will allow hospital operators to initiate strategies to

alleviate shortage in surgical blood supply

Stable Revenue and Cashflow

58,892 73,157 87,45596,170 104,209

0

100,000

FY07/08 FY08/09 FY09/10 FY10/11 FY11/12

Medical Accessories

5-year CARG=16%

Strategic Investments

• Group disposed 3% interest in its associate, Fortress Group Limited (A SPV privitized FunTalk

China in August 2011), for US$15mm in September 2011. After the disposal, Group’s

effective interest in Fortress Group Limited became 29.4%

• Fortress Group Limited contributed HK$94.5mm compared to HK$73.8mm in the prior

period, increased by 28%

15

period, increased by 28%

• Through Chinese herbal medicine business, the Group currently own a piece of prime land

in Shanghai. The land offers excellent prospects for appreciation once the property market

in China stabilises

Company Outlook

• Cord blood bank to further increase market penetration in Beijing andGuangdong, and future maiden contribution from its Zhejiang operation

• New hospital will contribute to Group upon completion

• GM-Medicare, medical insurance claim processing TPA to capture

Healthcare Services Segment:

16

• GM-Medicare, medical insurance claim processing TPA to capturesignificant unaddressed demands in a new industry in China

• New strategies to promote device sales to lower tier hospitals

• Drive for growth in accessories sales

• New products launch and innovations

Medical devices segment:

17

Q & A

Investor Relations Department

Email: ir@goldenmeditech.com

18

Email: ir@goldenmeditech.com

Tel: +852 3605 8180

Website: www.goldenmeditech.com